(Q34326476)

English

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Shahneen K Sandhu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Kyri Papadopoulos

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Peter C Fong

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Amita Patnaik

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Christina Messiou

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

David Olmos

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

George Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Brenda J Tromp

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Thomas A Puchalski

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Birge Berns

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Shobha Seetharam

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Johann S de Bono

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Anthony W Tolcher

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

6 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

71

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1041-1050

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385782%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

https://scigraph.springernature.com/pub.10.1007/s00280-013-2099-8

0 references

Monocyte chemoattractant protein-1 (MCP-1): an overview

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Chemokines and chemokine receptors: new insights into cancer-related inflammation.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 is a potent regulator of prostate cancer cell migration and proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Dose escalation methods in phase I cancer clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2099-8

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34326476&oldid=1991442999"